Effects of antiviral drug therapy on serum IL-1β, IL-6, IL-18 and TNF-α in patients with herpes zoster

doi:10.3877/cma.j.issn.1674-1358.2017.04.003

Abstract

Abstract:

Objective

To investigate the changes of the serum cytokines levels of interleukin (IL)-1β, IL-6, IL-18 and tumor necrosis factor-α (TNF-α) in patients with herpes zoster before and after the treatment of antiviral medication.

Methods

According to the inclusion criteria, total of 18 patients with herpes zoster in our hospital were selected. The levels of serum cytokines IL-1β, IL-6, IL-18 and TNF-α were detected before and after the treatment of antiviral drug therapy, respectively.

Results

After the treatment, the statistical results showed the levels of serum cytokines IL-1β (t = 18.46), IL-6 (t = 6.15), IL-18 (t = 21.50) and TNF-α (t = 10.95) of the 18 patients significantly decreased (all P < 0.001). The levels of serum cytokine IL-6 of 3 cases increased compared with the levels before treatment. The levels of serum cytokine TNF-α of 2 cases displayed no significantly change after treatment. Follow-up visits after one month, the patient with high level of IL-6 after the treatment of antiviral drug therapy felt neuropathic pain, which the symptom remit without any treatment. But one patient with high level of both IL-6 and TNF-α emerged post-herpetic neuralgia.

Conclusions

After the treatment of antiviral medication, the inflammatory condition had improved in all patients. But the status of sustained high levels of serum IL-6 and TNF-α may lead post-herpetic neuralgia.

Key words: Herpes zoster, Drug therapy, Cytokine, Neuralgia

Bingzheng Shen, Xiang Gao, Jie Wu, Yue Wu, Chengliang Zhu, Yan Yu. Effects of antiviral drug therapy on serum IL-1β, IL-6, IL-18 and TNF-α in patients with herpes zoster[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2017, 11(04): 326-329.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2017.04.003

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2017/V11/I04/326

Figures/Tables 2

References 26

[1]	傅伟. 更昔洛韦治疗带状疱疹的疗效观察[J]. 中国民族民间医药,2010,19(20):126.
[2]	Wu CL, Marsh A, Dworkin RH. The role of sympathetic nerve blocks in herpes zoster and postherpetic neuralgia[J]. Pain,2000,87(2):121-129.
[3]	张学军主编. 皮肤性病学[M]. 北京: 人民卫生出版社,2008:63-64.
[4]	钟敏, 曾因明, 柳垂亮, 等. 脊髓TNF-α, IL-1β和IL-6在神经病理性疼痛过程中的表达变化[J]. 中国疼痛医学杂志,2010,16(1):42-44.
[5]	Ohfu M, Masuzaki M, Inoue S, et al. Interleukin-6 in the cerebrospinal fluid of two patients with herpes zoster meningitis[J]. No To Hattatsu, 2001,33(3):270-275.
[6]	Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation[J]. Neurobiol Dis,1998,5(4):209-227.
[7]	陈大伟, 谢鹏, 邹德智, 等. 带状疱疹后遗神经痛患者血清IL-6水平与神经损伤的关系[J]. 中国神经免疫学和神经病学杂志,2005,12(3):140-142.
[8]	徐晓巍, 王金忠. 干扰素联合更昔洛韦治疗带状疱疹的临床疗效及对患者后遗神经痛及IL-6, IL-10的影响研究[J]. 中国生化药物杂志,2015,35(11):55-57.
[9]	张璇, 张玉萍, 郭智. IL-18的研究进展[J]. 实用癌症杂志,2012,27(5):533-535.
[10]	Okamura H, Tsutsui H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-γ production by T cells[J]. Nature,1995,378(6552):88-91.
[11]	Dnarello CA. IL-18: a TH1-inducing, pro-inflammatory cytokine and new member of the IL-1 family[J]. J Allergy Clin Immunol,1999,103(1):11-24.
[12]	郭斌杰, 陈德宇. 带状疱疹后遗神经痛与白介素和TNF-α的关系[J]. 西南军医,2012,14(1):115-116.
[13]	Amsler L, Malouli D, DeFilippis V. The inflammasome as a target of modulation by DNA viruses[J]. Future Virol, 2013,8(4):357-370.
[14]	赵延峰, 杨彦忠, 崔澂. 白细胞介素18的研究进展[J]. 医学综述,2010,16(21):3205-3209.
[15]	Ferreira J, Marques HH, Ferriani MPL, et al. Herpes zoster infection in childhood-onset systemic lupus erythematosus patients: a large multicenter study[J]. Lupus,2016,25(7):754-759.
[16]	宋萍, 郑成云. 白细胞介素-2协同白细胞介素-18活化自然杀伤细胞活性的作用[J]. 西安交通大学学报(医学版),2006,27(3):227-229.
[17]	Schönberg K, Rudolph J, Vonnahme M, et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms[J]. Cancer Res,2015,75(11):2187-2199.
[18]	Leng J, Zhang L, Yao H, et al. Antitumor effects of interleukin-18 gene-modified hepatocyte cell line on implanted liver carcinoma[J]. Chin Med J (Engl),2003,116(10):1475-1479.
[19]	田中秋, 邓立普. TNF-α, IL-6在全身炎症反应综合征表达的研究进展[J]. 蛇志,2008,20(4):275-278.
[20]	Campbell IK, Roberts LJ, Wicks IP. Molecular targets in immune-mediated diseases: the case of tumor necrosis factor and rheumatoid arthritis[J]. Immunol Cell Biol,2003,81(5):354-366.
[21]	Murdaca G, Spanò F, Contatore M, et al. Infection risk associated with anti-TNF-α agents: a review[J]. Expert Opin Drug Saf,2015,14(4):571-582.
[22]	韩玲娜, 王春雷, 李晓丽. TNF-α在神经病理性疼痛模型大鼠脑组织中的表达和作用[J]. 长治医学院学报,2009,23(4):247-249.
[23]	Chebli JMF, Gaburri PD, Chebli LA, et al. A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-alpha therapy[J]. Med Sci Monit,2014,26(20):487-498.
[24]	Yamaoka K. Benefit and risk of tofacitinib in the treatment of rheumatoid arthritis: a focus on herpes zoster[J]. Drug Saf,2016,39(9):823-840.
[25]	Wieseler-Frank J, Maier SF, Watkins LR. Central pro-inflammatory cytokines and pain enhancement[J]. Neurosignals,2005,14(4):166-174.
[26]	Zajkowska A, Garkowski A, Świerzbińska R, et al. Evaluation of chosen cytokine levels among patients with herpes zoster as ability to provide immune response[J]. PLoS one,2016,11(3):e0150301.

编号	性别	病程（d）	年龄（岁）	IL-1β		IL-6		IL-18		TNF-α
编号	性别	病程（d）	年龄（岁）	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
1	男	3	45	7.3	4.4	389.1	256.2	98.56	55.1	20.0	9.4
2	男	4	31	8.1	5.0	508.2	255.8	100.1	50.0	22.4	9.0
3	男	1	49	7.0	3.8	433.6	294.7	88.8	45.0	25.1	12.0
4	男	5	40	5.9	3.1	462.2	487.6	90.0	50.0	20.1	10.8
5	男	7	44	7.4	4.3	600.1	328.3	102.0	59.7	24.5	10.1
6	男	2	36	6.5	4.0	522.4	299.9	86.0	50.6	23.3	9.9
7	男	7	53	9.7	5.2	503.7	219.9	135.6	70.1	29.4	12.6
8	男	5	48	8.9	6.3	499.8	301.1	79.6	43.3	19.8	8.9
9	男	2	43	7.2	4.9	360.9	202.3	121.9	77.6	26.7	11.1
10	男	6	52	9.4	5.1	620.4	445.1	80.5	30.2	21.3	9.8
11	女	4	42	5.8	2.5	451.8	335.1	94.4	39.9	21.0	11.0
12	女	3	39	7.9	4.1	405.4	481.1	83.4	48.8	21.7	20.6
13	女	5	34	8.3	5.8	486.0	211.4	90.2	55.3	24.9	9.2
14	女	2	48	6.0	4.1	444.4	300.1	81.5	50.0	25.1	10.7
15	女	1	50	9.9	6.4	586.2	400.9	100.1	49.2	22.9	10.4
16	女	7	36	6.8	3.3	475.1	321.6	111.3	60.2	28.6	28.1
17	女	6	49	8.8	4.6	500.8	534.6	96.4	44.3	20.9	8.1
18	女	3	38	8.0	3.9	381.2	232.2	109.9	56.4	21.6	12.0

编号	性别	病程（d）	年龄（岁）	IL-1β		IL-6		IL-18		TNF-α
编号	性别	病程（d）	年龄（岁）	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
1	男	3	45	7.3	4.4	389.1	256.2	98.56	55.1	20.0	9.4
2	男	4	31	8.1	5.0	508.2	255.8	100.1	50.0	22.4	9.0
3	男	1	49	7.0	3.8	433.6	294.7	88.8	45.0	25.1	12.0
4	男	5	40	5.9	3.1	462.2	487.6	90.0	50.0	20.1	10.8
5	男	7	44	7.4	4.3	600.1	328.3	102.0	59.7	24.5	10.1
6	男	2	36	6.5	4.0	522.4	299.9	86.0	50.6	23.3	9.9
7	男	7	53	9.7	5.2	503.7	219.9	135.6	70.1	29.4	12.6
8	男	5	48	8.9	6.3	499.8	301.1	79.6	43.3	19.8	8.9
9	男	2	43	7.2	4.9	360.9	202.3	121.9	77.6	26.7	11.1
10	男	6	52	9.4	5.1	620.4	445.1	80.5	30.2	21.3	9.8
11	女	4	42	5.8	2.5	451.8	335.1	94.4	39.9	21.0	11.0
12	女	3	39	7.9	4.1	405.4	481.1	83.4	48.8	21.7	20.6
13	女	5	34	8.3	5.8	486.0	211.4	90.2	55.3	24.9	9.2
14	女	2	48	6.0	4.1	444.4	300.1	81.5	50.0	25.1	10.7
15	女	1	50	9.9	6.4	586.2	400.9	100.1	49.2	22.9	10.4
16	女	7	36	6.8	3.3	475.1	321.6	111.3	60.2	28.6	28.1
17	女	6	49	8.8	4.6	500.8	534.6	96.4	44.3	20.9	8.1
18	女	3	38	8.0	3.9	381.2	232.2	109.9	56.4	21.6	12.0

组别	IL-1β	IL-6	IL-18	TNF-α
治疗前	7.72 ± 1.28	479.52 ± 73.47	97.24 ± 14.98	23.29 ± 2.89
治疗后	4.49 ± 1.05	328.22 ± 101.38	51.98 ± 10.81	11.87 ± 4.86
t值	18.460	6.150	21.500	10.950
P值	< 0.001	< 0.001	< 0.001	< 0.001

组别	IL-1β	IL-6	IL-18	TNF-α
治疗前	7.72 ± 1.28	479.52 ± 73.47	97.24 ± 14.98	23.29 ± 2.89
治疗后	4.49 ± 1.05	328.22 ± 101.38	51.98 ± 10.81	11.87 ± 4.86
t值	18.460	6.150	21.500	10.950
P值	< 0.001	< 0.001	< 0.001	< 0.001

Please choose a citation manager

Content to export